FrancophonIA/ELRC3.0 huggingface dataset:
English: Yellow, convex, ovaloid tablet with a bevelled edge, with “T7” debossed on one side and “NVR” on
Slovenian: Rumena konveksna ovalna tableta z zaobljenim robom, z oznako “T7” vtisnjeno na eni strani in
English: Each tablet contains 300 mg aliskiren (as aliskiren hemifumarate) and 10 mg amlodipine (as
Slovenian: Ena tableta vsebuje 300 mg aliskirena (v obliki aliskirenijevega hemifumarata) in 10 mg amlodipina
English: Each tablet contains 150 mg aliskiren (as aliskiren hemifumarate) and 5 mg amlodipine (as
Slovenian: Ena tableta vsebuje 150 mg aliskirena (v obliki aliskirenijevega hemifumarata) in 5 mg amlodipina
English: Each tablet contains 150 mg aliskiren (as aliskiren hemifumarate) and 10 mg amlodipine (as
Slovenian: Ena tableta vsebuje 150 mg aliskirena (v obliki aliskirenijevega hemifumarata) in 10 mg amlodipina
English: Each film-coated tablet contains 150 mg aliskiren (as hemifumarate) and 5 mg amlodipine (as besylate).
Slovenian: Ena filmsko obložena tableta vsebuje 150 mg aliskirena (v obliki hemifumarata) in 5 mg amlodipina
English: The adverse reactions observed with Rasilamlo or with monotherapy with one or both of the two components are included in the table below.
Slovenian: V spodnji preglednici so navedeni neželeni učinki, ki so jih opažali pri uporabi zdravila Rasilamlo ali pri uporabi katere od obeh zdravilnih učinkovin v monoterapiji.
English: Each film-coated tablet contains 300 mg aliskiren (as hemifumarate) and 5 mg amlodipine (as besylate).
Slovenian: Ena filmsko obložena tableta vsebuje 300 mg aliskirena (v obliki hemifumarata) in 5 mg amlodipina
English: Arthralgia a,am
Slovenian: , ikterus a,am
English: • dry skin, rash, itchy rash
Slovenian: • suha koža, izpuščaj, srbeč izpuščaj
English: Each film-coated tablet contains 300 mg aliskiren (as hemifumarate) and 10 mg amlodipine (as besylate).
Slovenian: Ena filmsko obložena tableta vsebuje 300 mg aliskirena (v obliki hemifumarata) in 10 mg amlodipina
English: Each film-coated tablet contains 150 mg aliskiren (as hemifumarate) and 10 mg amlodipine (as besylate).
Slovenian: Ena filmsko obložena tableta vsebuje 150 mg aliskirena (v obliki hemifumarata) in 10 mg amlodipina
English: a, oral mucosal reactions a, rash a,am
Slovenian: a, reakcije ustne sluznice a,
English: What Rasilamlo looks like and contents of the pack Rasilamlo 150 mg/5 mg film-coated tablets are light yellow, convex, oval film-coated tablets, with “T2” debossed on one side and “NVR” on the other.
Slovenian: Rasilamlo 150 mg/5 mg filmsko obložene tablete so svetlo rumene konveksne ovalne filmsko obložene tablete z zaobljenim robom, z oznako “T2” vtisnjeno na eni strani in oznako “NVR” na
English: • severe upper stomach pain
Slovenian: • huda bolečina v zgornjem delu trebuha
English: Cellulose microcrystalline Crospovidone Povidone
Slovenian: Obloga hipromeloza makrogol smukec rumeni železov oksid (E172)
English: Steady-state plasma levels are reached after continuous administration for 7-8 days.
Slovenian: Plazemska koncentracija v stanju dinamičnega ravnovesja je dosežena po 7 do
English: The adverse reactions previously reported with one or both of the two active substances (aliskiren and amlodipine) of Rasilamlo and listed below may occur with
Slovenian: Pri uporabi zdravila Rasilamlo lahko pride do neželenih učinkov, ki so navedeni spodaj in o katerih so že poročali pri uporabi ene ali obeh posameznih učinkovin (aliskirena in amlodipina).
English: Hypersensitivity reactions including anaphylactic reactions have also been reported in post-marketing
Slovenian: Med zdravljenjem z aliskirenom je prišlo do preobčutljivostnih reakcij, vključno z anafilaktičnimi
English: Transporters
Slovenian: Preiskave
English: Liver enzyme increased a, weight increase weight decrease
Slovenian: Preiskave pogosti hiperkaliemija a občasni zvišane vrednosti jetrnih encimov a, povečanje telesne mase
English: Vial (glass)
Slovenian: Velikost pakiranja viala (steklo)
English: Ref.: EMEA/758620/2009 EMEA/H/C/557
Slovenian: : EMEA/758620/2009 EMEA/H/C/557
English: It should be given up to 15 minutes before or just after a meal.
Slovenian: Daje se do 15 minut pred obrokom ali takoj po njem.
English: 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@ema.europa.eu http://www.ema.europa.eu
Slovenian: 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea.europa.eu http://www.emea.europa.eu
English: The European Commission granted a marketing authorisation valid throughout the European Union for Apidra to Sanofi-Aventis Deutschland GmbH on 27 September 2004.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Apidra, veljavno po vseh Evropski uniji, odobrila družbi Sanofi-Aventis Deutschland GmbH dne 27. septembra 2004.
English: Other information about Apidra:
Slovenian: Druge informacije o zdravilu Apidra:
English: However, there was not enough information to show whether Apidra was effective in children aged below six years.
Slovenian: Vendar pa ni bilo dovolj podatkov, ki bi pokazali ali je zdravilo Apidra učinkovito pri otrocih, mlajših od šest let.
English: Apidra insulin glulisine EPAR summary for the public
Slovenian: Apidra insulin glulisin Povzetek EPAR za javnost
English: It must not be used in patients who already have hypoglycaemia.
Slovenian: Zdravilo se ne sme uporabljati pri bolnikih, ki že imajo hipoglikemijo.
English: Patients can inject Apidra under the skin themselves.
Slovenian: Bolniki si lahko zdravilo Apidra pod kožo vbrizgajo sami.
English: Apidra can also be injected into a vein, but this can only be done by a doctor or nurse.
Slovenian: Zdravilo Apidra se lahko injicira tudi v veno, vendar lahko to naredi samo zdravnik ali medicinsko osebje.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Apidra's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Apidra večje od z njim povezanih tveganj in priporočil, da se zanj odobri dovoljenje za promet.
English: The site of injection should be changed with each injection to avoid changes to the skin (such as thickening) that can make the insulin work less well than expected.
Slovenian: Mesto injiciranja je treba pri vsaki injekciji menjati, da se preprečijo spremembe na koži (kot je odebelitev), zaradi česar insulin lahko deluje slabše od pričakovanega.
English: What benefit has Apidra shown during the studies?
Slovenian: Kakšne koristi je zdravilo Apidra izkazalo med študijami?
English: Apidra doses might need to be adjusted when given with some other medicines that may have an effect on blood glucose levels.
Slovenian: Odmerke zdravila Apidra bo morda treba prilagoditi, če se jemlje sočasno z nekaterimi drugimi zdravili, ki bi lahko vplivala na raven glukoze v krvi.
English: In the first study of adults with type 1 diabetes, there was a decrease of 0.14% (from 7.60% to 7.46%) after six months, and a decrease of 0.14% for insulin lispro.
Slovenian: V prvi študiji z odraslimi bolniki s sladkorno boleznijo tipa 1 je prišlo do 0,14-odstotnega zmanjšanja (z 7,60 % na 7,46 %) po šestih mesecih ter 0,14-odstotnega zmanjšanja z insulinom lispro.
English: The most common side effect with Apidra (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels).
Slovenian: Najpogostejši neželeni učinek zdravila Apidra (opažen pri več kot 1 bolniku izmed 10) je hipoglikemija (nizka raven glukoze v krvi).
English: In type 2 diabetes (when the body is unable to use insulin effectively), Apidra has been studied in one study involving 878 adults.
Slovenian: Pri sladkorni bolezni tipa 2 (ko telo insulina ne more učinkovito izrabljati) je bilo zdravilo Apidra proučevano v eni študiji, ki je vključevala 878 odraslih bolnikov.
English: Apidra, used in combination with a long-acting insulin, has been studied in type 1 diabetes (when the body cannot produce insulin) in two studies involving a total of 1,549 adults and in one study involving 572 children and adolescents aged between four and 17 years.
Slovenian: Zdravilo Apidra, uporabljeno z insulinom z dolgotrajnim delovanjem, so proučevali pri sladkorni bolezni tipa 1(ko telo ne more proizvajati insulina) v dveh študijah s skupaj 1 549 odraslimi bolniki in v eni študiji s 572 otroki in mladostniki, starimi od štiri do 17 let.
English: It is supplied in vials, cartridges and prefilled disposable pens (OptiSet and SoloStar).
Slovenian: Na voljo je v vialah, injekcijskih vložkih in predhodno napolnjenih injekcijskih peresnikih za enkratno uporabo (OptiSet in SoloStar).
English: The patient's blood glucose (sugar) levels should be regularly tested to find the lowest effective dose.
Slovenian: Raven glukoze (sladkorja) v krvi bolnika je treba redno preverjati, da določimo najmanjši učinkovit odmerek.
English: The main measure of effectiveness was the change in levels of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Slovenian: Glavno merilo učinkovitosti je bila sprememba količine snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je glukoza v krvi nadzorovana.
English: Blood glucose control with Apidra was at least as effective as that with the comparator insulins.
Slovenian: Nadzor glukoze v krvi je bil z zdravilom Apidra vsaj tako učinkovit kot s primerjalnimi insulini.
English: The difference means that insulin glulisine acts more rapidly, and has a shorter duration of action than a short-acting human insulin.
Slovenian: Razlika je v tem, da insulin glulisin učinkuje hitreje in deluje manj časa kot humani insulin s kratkotrajnim delovanjem.
English: Apidra is used to treat patients aged six years or over with diabetes, when they need insulin.
Slovenian: Zdravilo Apidra se uporablja za zdravljenje bolnikov, starejših od 6 let, kadar potrebujejo insulin.
English: The active substance in Apidra, insulin glulisine, is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin glulisine.
Slovenian: Zdravilno učinkovino v zdravilu Apidra, insulin glulisin, proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, Izdela ga bakterija, ki je prejela gen (DNK), s katerim lahko tvori insulin glulisin.
English: Insulin glulisine is very slightly different from human insulin.
Slovenian: Insulin glulisin se zelo malo razlikuje od humanega insulina.
English: In all four studies, Apidra was compared with other insulins or insulin analogues (regular human insulin or insulin lispro).
Slovenian: V vseh štirih študijah so zdravilo Apidra primerjali z drugimi insulini ali analogi insulina (običajnim humanim insulinom ali insulinom lispro).
English: What is the risk associated with Apidra?
Slovenian: Kakšna tveganja so povezana z zdravilom Apidra?
English: Apidra should not be used in people who may be hypersensitive (allergic) to insulin glulisine or any of the other ingredients.
Slovenian: Zdravila Apidra ne smejo jemati osebe, ki utegnejo biti preobčutljive za (alergične na) insulin glulisin ali katero koli drugo sestavino zdravila.
English: Similar reductions were seen in the second study in adults, which compared Apidra with regular human insulin.
Slovenian: Podobna zmanjšanja so bila opažena v drugi študiji pri odraslih, v kateri so zdravilo Apidra primerjali z običajnim humanim insulinom.
English: Apidra is a short-acting insulin that is used in combination with intermediate- or long-acting insulins or insulin analogues (modified forms of insulin).
Slovenian: Zdravilo Apidra je insulin s kratkotrajnim delovanjem, ki se uporablja v kombinaciji z insulini s srednjedolgim ali dolgotrajnim delovanjem ali analogi insulina (spremenjenimi oblikami insulina).
English: Apidra is given by injection under the skin in the abdominal wall (tummy), the thigh or the shoulder, or by continuous infusion using an insulin pump.
Slovenian: Zdravilo Apidra se injicira pod kožo v trebušno steno, stegno ali ramo ali s kontinuirano infuzijo z insulinsko črpalko.
English: In adults with type 2 diabetes, there was a decrease in HbA1c of 0.46% after six months of Apidra, compared with 0.30% for regular human insulin.
Slovenian: Pri odraslih s sladkorno boleznijo tipa 2 je bilo z zdravilom Apidra doseženo 0,46-odstotno zmanjšanje HbA1c po šestih mesecih, v primerjavi z 0,30 % ob uporabi običajnega humanega insulina.
English: Why has Apidra been approved?
Slovenian: Zakaj je bilo zdravilo Apidra odobreno?
English: For the full list of all side effects reported with Apidra, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Apidra, glejte navodilo za uporabo.
English: In all of the studies, the change in the level of HbA1c seen with Apidra was similar to that seen with the comparator insulins.
Slovenian: V vseh študijah je bila sprememba ravni HbA1c, opažena z zdravilom Apidra, podobna spremembi, opaženi s primerjalnimi insulini.
English: It may also be used in combination with antidiabetes medicines taken by mouth.
Slovenian: Lahko se uporablja tudi v kombinaciji s peroralnimi zdravili proti sladkorni bolezni.
English: Apidra is a replacement insulin that is very similar to the insulin made by the body.
Slovenian: Zdravilo Apidra je nadomestni insulin, ki je zelo podoben insulinu, ki ga proizvaja telo.
English: The full EPAR for Apidra can be found here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Apidra je na voljo tukaj.
English: In this study, Apidra was used in combination with an intermediate-acting insulin and antidiabetes medicines taken by mouth.
Slovenian: V tej študiji je bilo zdravilo Apidra uporabljeno v kombinaciji z insulinom s srednjedolgim delovanjem ter peroralnimi zdravili proti sladkorni bolezni.
English: Apidra is a solution for injection that contains the active substance insulin glulisine.
Slovenian: Zdravilo Apidra je raztopina za injiciranje, ki vsebuje zdravilno učinkovino insulin glulisin.
English: In the study in children and adolescents, Apidra and insulin lispro produced similar changes in HbA1c after six months.
Slovenian: V študiji pri otrocih in mladostnikih so bile po šestih mesecih opažene podobne spremembe z zdravilom Apidra in insulinom lispro.
English: How has Apidra been studied?
Slovenian: Kako je bilo zdravilo Apidra raziskano?
English: What is Apidra used for?
Slovenian: Za kaj se zdravilo Apidra uporablja?
English: How does Apidra work?
Slovenian: Kako zdravilo Apidra deluje?
English: What is Apidra?
Slovenian: Kaj je zdravilo Apidra?
English: How is Apidra used?
Slovenian: Kako se zdravilo Apidra uporablja?
English: The full list is available in the Package Leaflet.
Slovenian: Za celoten seznam omejitev glejte navodilo za uporabo.
English: However, talk to your doctor first.
Slovenian: Kljub temu se o tem najprej pogovorite z zdravnikom.
English: (4) Not statistically significant.
Slovenian: (4) Ni statistično značilno.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 30 March 2009
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 30. marec 2009
English: Children above 5 years old
Slovenian: Otroci, starejši od 5 let
English: Control vaccine N=10,201
Slovenian: Kontrolno cepivo N = 10.201
English: This is so that you and your doctor can talk about what steps need to be taken to protect your child.
Slovenian: Ob tem obisku se boste z vašim zdravnikom lahko pogovorili, kakšne ukrepe je potrebno sprejeti za zaščito vašega otroka.
English: Remove the needle protector, which on occasion can be a little stiff.
Slovenian: Odstranite ščitnik igle; to gre lahko včasih nekoliko trdo.
English: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Slovenian: Za izboljšanje sledljivosti bioloških zdravil morata biti jasno zabeležena ime in številka serije uporabljenega zdravila.
English: Please speak to your doctor for information on the number and timing of injections for your child.
Slovenian: Prosimo, pogovorite se s svojim zdravnikom o številu in časovnem razporedu injekcij, ki jih bo dobil vaš otrok.
English: If not used within 28 days it should be discarded.
Slovenian: Če ni porabljeno v 28 dneh, ga morate zavreči.
English: • allergic reactions such as skin allergies
Slovenian: • alergijske reakcije, npr. alergije na koži
English: The persistence of protection against B-CAP and C-CAP beyond the age of 36 months is currently not established.
Slovenian: Trajanje zaščite proti B-CAP in C-CAP v starosti nad 36 mesecev še ni bilo ocenjeno.
English: Antipyretic treatment should be initiated according to local treatment guidelines.
Slovenian: Antipiretično zdravljenje je potrebno začeti v skladu z lokalnimi smernicami zdravljenja.
English: If your child misses an injection
Slovenian: Če otrok zamudi eno injekcijo
English: Adverse reactions (for all age groups)have been categorised by frequency.
Slovenian: Neželene učinke (za vse starostne skupine) so razvrstili po pogostnosti.
English: In addition, OPA GMTs were in same ranges for both groups.
Slovenian: Poleg tega je bila GMT OPA v obeh skupinah v enakem razponu.
English: • You will be told when your child should come back for the next injections.
Slovenian: • Zdravnik vam bo povedal, kdaj mora otrok priti po naslednje injekcije.
English: • Do not use this medicine after the expiry date which is stated on the carton.
Slovenian: • Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
English: It is not known whether the reduction in antibody levels has an impact on the protection against pneumococcal disease.
Slovenian: Ni znano ali znižanje ravni protiteles vpliva na zaščito proti pnevmokokni bolezni.
English: For children above 5 years old safety and efficacy of the vaccine have not been established, therefore vaccination of these children is not recommended.
Slovenian: Pri otrocih starejših od 5 let varnost in učinkovitost cepiva nista bili ocenjeni, zato cepljenje teh otrok ni priporočljivo.
English: As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.
Slovenian: Ker je korist cepljenja v tej skupini otrok velika, cepljenja ne bi smeli izpustiti ali odložiti.
English: However, taken together there was a trend for decrease in overall pneumococcal carriage.
Slovenian: V celoti pa je obstajal trend k zmanjšanju celotnega nosilstva pnevmokokov.
English: If not used within 6 hours it should be discarded.
Slovenian: Če ni porabljeno v 6 urah, ga morate zavreči.
English: The majority of these reactions were of mild to moderate severity and were not long lasting.
Slovenian: V večini primerov sta bila učinka blaga do zmerno huda in nista trajala dolgo.
English: Synflorix is not intended for use in adults.
Slovenian: Synflorix ni namenjen za uporabo pri odraslih.
English: When using a multidose vial, each 0.5 ml dose should be withdrawn using a sterile needle and syringe; precautions should be taken to avoid contamination of the contents.
Slovenian: Ko uporabljate večodmerno vialo, morate vsak 0,5-ml odmerek izvleči s sterilno iglo in brizgo; upoštevati morate previdnostne ukrepe, da boste preprečili onesnaženje vsebine.
English: Vaccine efficacy n
Slovenian: Učinkovitost cepiva n
English: Incidence per 100,000 person years
Slovenian: Incidenca na 100.000 človek-let
English: CI Confidence Interval
Slovenian: IZ interval zaupanja
English: Read all of this leaflet carefully before your child receives this vaccine because it contains important information for you.
Slovenian: Preden vaš otrok prične dobivati to cepivo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
English: In both studies there were significant decrease of individual serotypes 6B and 19F.
Slovenian: V obeh študijah so zabeležili značilno zmanjšanje individualnih serotipov 6B in 19F.
English: For adsorbent, see section 2.
Slovenian: Za adsorbente glejte poglavje 2.
English: The use of Synflorix should be determined on the basis of official recommendations taking into consideration the impact on pneumococcal diseases in different age groups as well as the variability of the epidemiology in different geographical areas.
Slovenian: Uporabo cepiva Synflorix je treba določiti na osnovi uradnih priporočil, upoštevaje vpliv pnevmokoknih bolezni po starostnih skupinah ter variabilnost epidemiologije na različnih geografskih območjih.
English: 1 adsorbed on aluminium phosphate
Slovenian: 1 adsorbiran na aluminijev fosfat
English: Pre-booster GMCs (8 to 12 months after the last primary dose) were generally similar for the two vaccines.
Slovenian: Predobnovitvena GMC (8 do 12 mesecev po zadnjem primarnem odmerku) je bila za obe cepivi na splošno podobna.
English: For children > 12 months of age, the risk of pain at the injection site may increase with increasing age.
Slovenian: Pri otrocih, starejših od 12 mesecev, se tveganje bolečin na mestu injiciranja morda povečuje z naraščajočo starostjo.
English: The vaccine efficacy against B-CAP observed at the interim analysis is presented below (table 2).
Slovenian: Učinkovitost cepiva proti B-CAP, ugotovljena pri vmesni analizi, je prikazana spodaj (preglednica 2).
English: Instructions for administration of the vaccine 1.
Slovenian: Navodila za injiciranje cepiva 1.
English: Do not administer intravascularly.
Slovenian: Ne injicirajte intravaskularno.
English: Pneumonia of different aetiologies is a leading cause of childhood morbidity and mortality globally.
Slovenian: Pljučnica različnih etiologij je po vsem svetu eden vodilnih vzrokov obolevnosti in umrljivosti v otroštvu.
English: Vaccine efficacy results in children > 36 months of age suggest a waning of protection.
Slovenian: Rezultati učinkovitosti cepiva pri otrocih, starejših od 36 mesecev, kažejo na upad zaščite.
English: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Slovenian: Zaradi pomanjkanja študij kompatibilnosti cepiva ne smete mešati z drugimi zdravili.
English: In general, comparable vaccine responses were observed for the different schedules, although somewhat higher immune responses were noted for the 2-4-6 month schedule.
Slovenian: Na splošno so pri različnih časovnih razporedih opažali primerljive odzive na cepivo, čeprav so bili imunski odzivi pri razporedu 2-4-6 mesecev nekoliko večji.
English: (95% CI: 7.7; 34.2)
Slovenian: (95 % IZ: 7,7, 34,2)
English: (4) Individual serotypes for which statistical significance was reached in the effectiveness analysis controlling for confounding factors (no adjustment for multiplicity performed).
Slovenian: (4) Posamezni serotipi, za katere je bila v analizi učinkovitosti dosežena statistična značilnost ob upoštevanju drugih vpletenih dejavnikov (brez korekcije za večkratne primerjave).
English: It is used to help protect your child from 6 weeks up to 5 years of age against: a bacteria called ‘Streptococcus pneumoniae'.
Slovenian: Uporabljamo ga za zaščito otrok od 6. tedna do 5. leta starosti pred: bakterijo, imenovano "Streptococcus pneumoniae".
English: Control(2)
Slovenian: Kontrole(2)
English: The implications of these findings for protective efficacy are not known.
Slovenian: Ni znano, kaj ti izsledki pomenijo za zaščitno učinkovitost.
English: Use with systemic immunosuppressive medicinal products
Slovenian: Uporaba s sistemskimi imunosupresivnimi zdravili
English: At least six months after the last injection, your child will receive an additional injection (booster).
Slovenian: Vsaj šest mesecev po zadnji injekciji bo otrok dobil še dodatno injekcijo (obnovitveni odmerek).
English: In prospective studies, Streptococcus pneumoniae was estimated to be responsible for 30-50% of pneumonia cases.
Slovenian: V prospektivnih študijah je bilo ocenjeno, da je za 30-50 % primerov bakterijskih pljučnic odgovoren Streptococcus pneumoniae.